rct
    2016
    High Quality

    Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial

    Andresen SR, Bing J, Hansen RM, Biering-Sorensen F, Johannesen IL, Hagen EM, Rice ASC, Nielsen JF, Bach FW, Finnerup NB

    Published in Pain

    Methodology

    Randomized, double-blind, placebo-controlled trial of ultramicronized PEA 600 mg twice daily for 12 weeks in spinal cord injury neuropathic pain

    Key Findings

    Ultramicronized PEA did not reduce neuropathic pain intensity more than placebo

    Conclusions

    PEA was not effective for neuropathic pain after spinal cord injury

    Limitations

    Single pain population; may not generalize to inflammatory pain states

    Supplements Studied

    PEA
    Compound

    Ultramicronized PEA did not reduce neuropathic pain intensity more than placebo

    Outcomes Measured

    Nerve Pain Relief

    Ultramicronized PEA did not reduce neuropathic pain intensity more than placebo

    Related Health Concerns

    Peripheral Neuropathy
    Nerve Pain (Neuropathy)

    Study Details

    Year:2016
    Sample Size:73
    Duration:12 weeks
    Quality Score:9/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.